Severe mental illness (SMI), a group of psychiatric diagnoses including schizophrenia, schizoaffective disorder, and bipolar disorder, is a major public health concern with a substantial impact on many aspects of patients’ daily lives,Reference Cohen, Meesters and Zhao1–Reference Hendrie, Tu, Tabbey, Purnell, Ambuehl and Callahan3 as well as on medical service provision and family caregivers.Reference De Hert, Cohen, Bobes, Cetkovich-Bakmas, Leucht and Ndetei4–Reference Tiihonen, Lonnqvist, Wahlbeck, Klaukka, Niskanen and Tanskanen6 The direct and indirect long-term health consequences of SMI are reflected in its profound influence on general health, for which all-cause mortality is commonly used as a comprehensive indicator.Reference Brink, Green, Bojesen, Lamberti, Conwell and Andersen2,Reference Tiihonen, Lonnqvist, Wahlbeck, Klaukka, Niskanen and Tanskanen6–Reference Talaslahti, Alanen, Hakko, Isohanni, Hakkinen and Leinonen9 Studies from various clinical settings and countries, including participants with a wide variety of socioeconomic backgrounds, have reported consistent results of significantly elevated all-cause mortality, with two- to three-fold increases in relative risk leading to a reduction in life expectancy of almost 15 years.Reference Brink, Green, Bojesen, Lamberti, Conwell and Andersen2,Reference Hendrie, Tu, Tabbey, Purnell, Ambuehl and Callahan3,Reference Tiihonen, Lonnqvist, Wahlbeck, Klaukka, Niskanen and Tanskanen6–Reference Reininghaus, Dutta, Dazzan, Doody, Fearon and Lappin8,Reference Chang, Hayes, Broadbent, Fernandes, Lee and Hotopf10–Reference Westman, Hallgren, Wahlbeck, Erlinge, Alfredsson and Osby15 In past decades, the gap in all-cause mortality between people living with SMI and the general population has persisted or even broadened.Reference Hoang, Stewart and Goldacre16 Potential reasons include adverse lifestyle factors, poorer healthcare utilisation, disparities in access to health services and side-effects of long-term psychotropic medication.Reference Babic, Maslov, Martinac, Nikolic, Uzun and Kozumplik17–Reference Cosci and Chouinard23 Among people with SMI, unnatural causes of death (i.e. homicide and suicide) have been found to be of particular importance, especially for those who died at a younger age.Reference Reininghaus, Dutta, Dazzan, Doody, Fearon and Lappin8,Reference Westman, Eriksson, Gissler, Hallgren, Prieto and Bobo14 However, natural causes of death have been estimated to contribute to as much as 80% of lost life expectancy among people with SMI in comparison with the general population, especially disorders of the circulatory system (mostly cardiovascular diseases), which are the leading cause of death for both sexes.Reference Hendrie, Tu, Tabbey, Purnell, Ambuehl and Callahan3,Reference Westman, Eriksson, Gissler, Hallgren, Prieto and Bobo14,Reference Westman, Hallgren, Wahlbeck, Erlinge, Alfredsson and Osby15,Reference Jayatilleke, Hayes, Dutta, Shetty, Hotopf and Chang24 Even in older individuals, SMI remains associated with two- or three-fold elevated all-cause mortality.Reference Almeida, Hankey, Yeap, Golledge, Norman and Flicker25–Reference Talaslahti, Alanen, Hakko, Isohanni, Kampman and Hakkinen27
Clinical management strategies for the SMI population emphasise the need to deal with increasing mental and physical healthcare requirements.Reference Meesters28,Reference Pearson, Siskind, Hubbard, Gordon, Coulson and Warren29 To address this issue, which is of particular research interest, further investigations into healthcare utilisation and disparities in access to health services for people with SMI have been suggested.Reference De Hert, Cohen, Bobes, Cetkovich-Bakmas, Leucht and Ndetei4,Reference Babic, Maslov, Martinac, Nikolic, Uzun and Kozumplik17,Reference Chang18,Reference Arbus, Clement, Bougerol, Fremont, Lancrenon and Camus30,Reference Muralidharan, Klingaman, Prior, Molinari and Goldberg31 As well as the psychopathologic manifestations of SMI, research has focused on health challenges met by older people living with SMI, with the ageing of SMI population.Reference Pearson, Siskind, Hubbard, Gordon, Coulson and Warren29 Compared with studies of mortality,Reference Talaslahti, Alanen, Hakko, Isohanni, Hakkinen and Leinonen9,Reference Meesters, Comijs, Smit, Eikelenboom, de Haan and Beekman26 studies of physical comorbidities in older people with SMI have had relative small sample sizes; this has meant that only a certain number of major disorders could be analysed because of the limited statistical power,Reference Brink, Green, Bojesen, Lamberti, Conwell and Andersen2,Reference Hendrie, Tu, Tabbey, Purnell, Ambuehl and Callahan3,Reference Crump, Winkleby, Sundquist and Sundquist7,Reference Brink, Green, Bojesen, Lamberti, Conwell and Andersen32–Reference Beunders, Kok, Kosmas, Beekman, Sonnenberg and Schouws34 preventing a comprehensive and detailed clinical picture from being obtained. Moreover, inconsistent findings have been reported regarding the risk of hospital admission for physical illness and length of hospital stay, which is a surrogate indicator of clinical severity and complexity at admission.Reference Hendrie, Tu, Tabbey, Purnell, Ambuehl and Callahan3,Reference Brink, Green, Bojesen, Lamberti, Conwell and Andersen32 Consequently, the issue of comorbidity in older people with SMI has not been fully addressed.
In this study, we aimed to systematically evaluate the risks of hospital admission across the full range of discharge diagnoses in a cohort consisting of older people with SMI from a population-based psychiatric case registry database in a geographic area of south London, UK. Lengths of hospital stay for major causes of hospital admission were also compared between this cohort and their counterparts in the general population as an indicator of disease severity and clinical complexity at admission.
Method
Setting of data source
Data were obtained for four south London boroughs (Croydon, Lambeth, Lewisham and Southwark), the geographically defined catchment area for the South London and Maudsley NHS Foundation Trust (SLaM), which has 1.36 million residents according to the 2011 UK Census. SLaM offers comprehensive secondary mental health services to this catchment area, providing in-patient care, community services, forensic services and liaison services to local general hospitals. Since 2006, all SLaM services have been using electronic mental health records. The SLaM Biomedical Research Centre Case Register was set up as a data resource to enable research use of complete but de-identified data from electronic health records via the Clinical Record Interactive Search (CRIS) platform, launched in 2008.Reference Perera, Broadbent, Callard, Chang, Downs and Dutta35
The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human subjects were approved by the Oxford Research Ethics Committee C (reference number: 23/SC/0257) for secondary data analyses under a rigorous monitoring framework and security model with patient-led governance regulations.
Study cohort and covariates
Applying a retrospective cohort study design, we constructed a cohort of older patients (>60 years old) with a previous primary or secondary diagnosis of a disorder classified by the World Health Organization ICD-10 under code F20 (schizophrenia), F25 (schizoaffective disorders) or F31 (bipolar disorders) before or during the observation period of 1 Apr 2007 to 31 Mar 2016. Diagnoses were ascertained from structured fields supplemented by a natural language processing algorithm for diagnostic statements in open-text fields developed by the Generalised Architecture for Text Engineering software.Reference Chandran, Robbins, Chang, Shetty, Sanyal and Downs36 To compare our research outcomes with those of previous studies,Reference Arbus, Clement, Bougerol, Fremont, Lancrenon and Camus30,Reference Meesters, de Haan, Comijs, Stek, Smeets-Janssen and Weeda37 the criterion of >60 years old was used to define older people with SMI. Each eligible participant had to be 60 years old or older at the beginning of the observation period (1 Apr 2007) for those whose earliest SMI diagnosis was confirmed before the observation period; on the first date of SMI diagnosis, if the diagnosis was given later in this period; or turning 60 years old or older during follow-up. Sex and ethnicity were also obtained from structured fields in CRIS. Date of admission to a hospital after SMI diagnosis in the observation period and corresponding diagnoses at discharge were retrieved from a linkage to Hospital Episodes Statistics (HES), a national data resource providing details of all admissions to National Health Service (NHS) hospitals in England. The linkage between CRIS and HES data-sets covering the SLaM catchment areas was performed anonymously by the NHS Health and Social Care Information Centre (now NHS Digital).
Statistical analysis
As the first step, standardised admission ratios (SARs) were calculated for the cohort of older people with SMI served by SLaM, considering age, sex and fiscal year at risk of admission (1 April to 31 March of two consecutive years) as adjusted confounders, compared with the general population in the SLaM catchment area of the same age range as the ‘standard population’ in indirect standardisation. Age strata were classified by 5-year age bands, i.e. 60–64, 65–69, … , and 90+ years old. Age and sex structure of the standard population was derived from the 2011 UK Census to generate age- and sex-specific admission rates with the hospital admission data from HES linkage in each fiscal year. For each SAR, the numerator was the ‘observed’ number of admissions experienced by CRIS cohort members, whereas the denominator of the SAR was the ‘expected’ number of hospital admission events among the SMI subjects obtained by multiplying the observed admission rate of the standard (i.e. general) population by the number of individuals with SMI and summing over fiscal year–age–sex strata, as a random variable. SARs were first calculated for all primary discharge diagnoses in the observation period and then by sex and ICD-10 chapter of physiologic system of disorders, following a standard approach.Reference Fok, Chang, Broadbent, Stewart and Moran38 Alternatively, SARs were recalculated by eliminating repeated admissions for the same diagnosis code in a fiscal year as a sensitivity analysis to avoid exaggeration by addressing the potential issue of most of the admissions pertaining to a relatively small group of people.
The second comparison evaluated the association of SMI with the duration of hospital stay (in days) for major causes of admission, defined by the primary diagnosis ICD-10 code at discharge for the first observed admission episode in the observation period. On the basis of disease burden to society and the healthcare system, the top five major categories according to admission numbers comprised respiratory system (ICD-10 codes: J00–J99), mixed group of heterogeneous diagnoses (symptoms, signs and findings not elsewhere classified: R00–R99), circulatory system (I00–I99), genitourinary system: urinary conditions (N00–N39) and digestive system (K00–K93); these were taken forward for further analyses, except the category R00–R99. To avoid violating the independent observation assumption (i.e. every observed subject must be independent from others in a random sample), we only included the first discharge diagnosis for admissions across all years. For each SMI case of first hospital admission, up to four non-SMI comparison subjects with the same primary discharge diagnosis of the first three ICD-10 code characters were randomly selected from the general population of the SLaM catchment area, matched by age within a year and sex. Univariable analyses for estimating the effects of SMI among older people and multivariable analyses for further confounding controls were performed on hospital stay duration in days for each of these major causes of admission by linear regression, with matching addressing the study design issue of dependent data by using ‘clusters’ of matching groups specified in the commands for each linear regression. Besides age and sex, the other adjusted confounders were ethnicity (classified as ‘White’, ‘Black’, ‘south Asian’, ‘east Asian’ and ‘others/mixed/unknown’), discharge method (including ‘clinical advice’, ‘clinical consent’, ‘self-discharged’, ‘death’ and ‘others’) and number of physical comorbidities besides the discharge diagnosis group itself, also retrieved from the HES linkage. All the analyses were conducted using Stata statistical software, version 12.1 (StataCorp., College Station, Texas, USA), and statistical significance was set to 0.05 (alpha level) in two-tailed tests.
Results
Study subject characteristics
Data for a total of 4175 cohort members older than 60 years old and living with SMI during the 9-year observation period with 26 579 person-years contributed were assembled from CRIS, containing electronic health records of over 305 000 SLaM patients at the moment of data retrieval (details shown in Fig. 1). Among them, 1802 were male (43.2%). More details of this study cohort including person-year breakdowns by sex, age group and at-risk fiscal years (1 April 2007 to 31 March 2016) are shown in Supplementary Table 1 available at https://doi.org/10.1192/bjo.2024.765. During the observation period, 10 342 hospital admissions were detected. For all these admission events, 41.6% (4303 admissions) were experienced by males and 58.4% (6039 admissions) by females. For both sexes, the most common cause of first admission was illness of the respiratory system (ICD-10 codes: J00–J99, involving 702 events for males and 954 for females), followed by the group of unspecified conditions: symptoms, signs and findings not elsewhere classified (R00–R99) with 1445 events.
Relative risks of admission
The overall SAR for our cohort was 5.15 (95% CI: 5.05, 5.25), with 4.82 (95% CI: 4.68, 4.97) for males and 5.41 (95% CI: 5.27, 5.55) for females. SARs ranked according to discharge diagnostic subgroups are displayed in Table 1. As SMI is a group of lifelong conditions, it was not surprising to detect extreme values among the SARs for mental and behaviour disorders (ICD-10 codes: F00–F99), even in the latter life stages. These were excluded from further analyses. Among all physical illnesses, the SAR of 8.49 (95% CI: 7.71, 9.32) for endocrine and metabolic diseases (E00–E90) was particularly notable in terms of effect size (magnitude of relative risk estimated by SAR), followed by urinary conditions (N00–N39), eye conditions (H00–H59) and then respiratory diseases (J00–J99). Among the top five major causes of admissions in terms of the number of admissions (ignoring the group R00–R99), overall SARs ranged from 3.87 for circulatory system (I00–I99) and 4.56 for digestive system (K00–K93) to 6.80 for respiratory system (J00–J99) and 6.99 for genitourinary system: urinary conditions (N00–N39). The SAR for R00–R99 was as high as 6.56 (95% CI: 6.22, 6.90), with 6.02 (95% CI: 5.55, 6.53) for men and 6.99 (95% CI: 6.53, 7.47) for women. In sensitivity analyses excluding multiple admissions for the same discharge diagnosis in a fiscal year (resulting in 15.51% of admissions, n = 1604, removed), findings were broadly similar (Table 2, also ranked according to discharge diagnostic subgroup).
a. Standard population: residents in London boroughs of Southwark, Croydon, Lambeth and Lewisham according to 2011 UK Census.
b. 95% CI for standardised admission ratio (SAR) = exp[ln(SAR^) ± 1.96 × (1/observed number1/2)], where SAR^ is the estimated value of SAR = (observed number of admissions)/(expected number of admissions); Z 1−2/α = Z 0.975 = 1.96.Reference Rothman, Greenland, Rothman, Greenland and Lash55
* Statistical significance (P-value < 0.05).
a. Standard population: residents of London boroughs of Southwark, Croydon, Lambeth and Lewisham according to 2011 UK Census.
b. 95% CI for standardised admission ratio (SAR) = exp[ln(SAR^) ± 1.96 × (1/observed number1/2)], where SAR^ is the estimated value of SAR = (observed number of admissions)/(expected number of admissions); Z 1−2/α = Z 0.975 = 1.96.Reference Rothman, Greenland, Rothman, Greenland and Lash55
* P < 0.05.
Comparisons of length of first hospital stay
In the analyses on length of first hospital stay in days for major discharge diagnoses (excluding admissions for ICD-10 codes R00–R99, as above), the mean length of first hospital stay for elders with SMI admitted for circulatory system diseases was 12.6 (s.d. = 22.2) days, whereas that for matched non-SMI elders was 9.6 (s.d. = 14.7) days. For other major admission causes, the lengths of stay were 10.6 (s.d. = 17.9) days for digestive system diseases, 13.4 (s.d. = 20.0) days for respiratory system diseases and 12.4 (s.d. = 14.7) days for urinary diseases among elders with SMI, all showing statistical significance in comparison with the matched comparison groups. According to the linear regression, older people with SMI admitted to hospitals stayed 3.10 days longer (95% CI: 1.42, 4.78) on average for illnesses of the circulatory system, 2.76 days longer (95% CI: 1.23, 4.30) for illnesses of the respiratory system, 3.11 days longer (95% CI: 1.49, 4.73) for digestive system illnesses and 1.42 days longer (95% CI: 0.05, 2.79) for genitourinary system illnesses: urinary conditions, after controlling for confounders (Table 3).
a. Adjusted for ethnicity, method of discharge and number of other physical comorbidities.
* P < 0.05.
Discussion
Main findings
In the present work, we investigated the relation between mental and physical illness using data from the largest single secondary mental health service provider in Western Europe to form a cohort of older people with SMI. Major diagnostic groups for admissions included a diverse range of illnesses of the respiratory, circulatory, urinary and digestive systems, as well as a group of diagnoses for ‘symptoms, signs and findings not elsewhere classified’ covered by the R codes in the ICD-10. After controlling for confounding from age, sex and fiscal year by indirect standardisation, the presence of SMI in older people was found to be related to worse physical health, with nearly five-fold elevated risks of overall hospital admission; endocrine and metabolic disorders were the leading cause of admission, followed by urinary conditions, eye conditions and then respiratory diseases. Length of hospital stay, a surrogate indicator of clinical severity and complexity of conditions at admission, was significantly longer for the major admission causes in our cohort, with potential confounders considered. Although the classification of admission causes was relatively broad, it provided a comprehensive picture of the health challenges faced by elders with SMI. Adding to existing evidence in the literature, we found that SMI profoundly affects individuals throughout life, influencing mental and physical health over time and affecting daily living, as well as being associated with additional physical health challenges during ageing.Reference Cohen, Meesters and Zhao1,Reference Meesters28,Reference Beunders, Kok, Kosmas, Beekman, Sonnenberg and Schouws34,Reference Cohen, Vahia, Reyes, Diwan, Bankole and Palekar39 Although older people with SMI have survived potential causes of death in earlier life stages, physical illnesses still affect these individuals in later life.Reference Hendrie, Tu, Tabbey, Purnell, Ambuehl and Callahan3,Reference De Hert, Correll, Bobes, Cetkovich-Bakmas, Cohen and Asai5,Reference Almeida, Hankey, Yeap, Golledge, Norman and Flicker25,Reference Arbus, Clement, Bougerol, Fremont, Lancrenon and Camus30,Reference Jeste and Maglione40,Reference Kalache, Mulsant, Davies, Liu, Voineskos and Butters41
Comparison with previous studies and impact on clinical practice
Previous studies have mainly concentrated on mortality or morbidity due to cardiovascular diseases in people with SMI, which have been attributed to obesity and metabolic disorders.Reference Crump, Winkleby, Sundquist and Sundquist7,Reference Lahti, Tiihonen, Wildgust, Beary, Hodgson and Kajantie13–Reference Westman, Hallgren, Wahlbeck, Erlinge, Alfredsson and Osby15 Unhealthy lifestyles, including smoking, alcohol consumption, lack of exercise and poorer psychosocial functions are widely accepted risk factors for vulnerability in people with SMI.Reference Babic, Maslov, Martinac, Nikolic, Uzun and Kozumplik17–Reference Vermeulen, van Rooijen, Doedens, Numminen, van Tricht and de Haan22 Self-neglect has been proposed as another psychosocial functioning issue that results in higher morbidity and need to be admitted for treatments, as well as higher mortality among people with SMI.Reference Wu, Chang, Hayes, Broadbent, Hotopf and Stewart42 The autonomic nervous system (ANS) is part of the peripheral nervous system innervating the organs and systems of major involuntary physiologic processes throughout the body, with involvement in regulation of body temperature, blood pressure, heart rate, digestion functions, and even emotional and/or behavioural responses. Given the diverse functions of the ANS, autonomic dysfunction has been proposed as an explanation for the wide range of conditions observed in people with SMI, based on evidence.Reference Pearson, Siskind, Hubbard, Gordon, Coulson and Warren29,Reference Alvares, Quintana, Hickie and Guastella43 ANS dysfunction, also called autonomic dysfunction, has been found to be associated with increased cardiovascular disease risk in individuals with psychiatric disorders, primarily owing to reduced heart rate variability caused not only by the disorders themselves but also by the use of psychotropic medications across various psychiatric disorders, suggesting a fundamental mechanism for elevation of cardiovascular risk.Reference Alvares, Quintana, Hickie and Guastella43 Furthermore, long-term use of antipsychotics and frequent polypharmacy for psychotropic medication, including antidepressants, lithium and anticonvulsants,Reference Babic, Maslov, Martinac, Nikolic, Uzun and Kozumplik17,Reference Correll, Detraux, De Lepeleire and De Hert19,Reference Cosci and Chouinard23 may increase adverse effects among people with SMI in later life.Reference De Hert, Correll, Bobes, Cetkovich-Bakmas, Cohen and Asai5,Reference Babic, Maslov, Martinac, Nikolic, Uzun and Kozumplik17,Reference Tiihonen, Mittendorfer-Rutz, Torniainen, Alexanderson and Tanskanen44 In practice, somatic complaints of people with SMI often prompt extensive evaluations during hospital admissions, but symptoms/signs remain diagnostically non-specific despite advanced testing ruling out major medical disorders. Clinicians in specialisms besides psychiatry may benefit from additional training in communicating with this specific vulnerable population with clinical complexity, as poor psychosocial functioning can make diagnosis difficult. How to minimise impacts of these metabolic effects of psychotropic medication as well as direct/indirect influences of autonomic dysfunction in older people with SMI are challenges for clinicians and caregivers.
Explanation of outcomes
Concerning eye conditions, visual processing impairments have been well characterised in schizophrenia and discussed for decades, and there is some evidence of common genetic factors.Reference Silverstein and Rosen45 As well as ocular disorders secondary to diabetes and hypertension, elevated risks of nystagmus, strabismus and poorer visual acuity have been noted among people with schizophrenia.Reference Torrey and Yolken46 An increased relative risk of ocular neurovascular conditions, especially glaucoma, was found among people with bipolar disorder, major depressive disorder and schizophrenia in a population-based study in Taiwan,Reference Liu, Kang, Lin, Wu, Liu and Kuo47 consistent with our findings.
Well-characterised side-effects of long-term use of antipsychotics are known to increase the risks of respiratory, endocrine, digestive and urinary conditions.Reference Babic, Maslov, Martinac, Nikolic, Uzun and Kozumplik17,Reference Mazereel, Detraux, Vancampfort, van Winkel and De Hert20,Reference Stogios, Gdanski, Gerretsen, Chintoh, Graff-Guerrero and Rajji48 However, our research also revealed an increased risk of admission for unspecified symptoms or signs (ICD-10 codes: R00–R99), which has not been specifically reported elsewhere in the literature; this warrants further investigations of these non-specific causes of admissions in older people with SMI. As well as the adverse effects of chronic exposure to antipsychotics and unhealthy lifestyle factors, autonomic dysfunction, with concurrent increases in sympathetic activity and decreases in parasympathetic activity caused by SMI itself and psychotropic medications, may further worsen the physical health of people with SMI.Reference Stogios, Gdanski, Gerretsen, Chintoh, Graff-Guerrero and Rajji48 The vagus nerve could be of particular importance with respect to digestive comorbidities in the SMI population, as it is part of the ANS and functions as a major mediator of bidirectional communication in the gut–brain axis, regulating the digestive functions of regional gut motility, digestive juice secretion, duct wall permeability, and even mucosal immune responses, with subtle influences on the composition and activity of the gut microbiome.Reference Martin, Osadchiy, Kalani and Mayer49 In summary, although autonomic dysfunction has been partially implicated in physical illnesses of people with SMI, further investigations into the underlying mechanisms for each significant physical health concern are warranted.
Advantages and disadvantages
A key strength of our research was the population-based data source with nearly complete coverage of the population in the catchment areas, indicating that this sample of older people with SMI was representative of those in the urban/suburban UK population. Use of natural language processing techniques to ascertain inclusion diagnoses further strengthened this advantage.Reference Chandran, Robbins, Chang, Shetty, Sanyal and Downs36 The temporal relationship between pre-existing SMI and consequent admission events was adequately established with a retrospective cohort study design. In addition, there was fairly complete ascertainment of hospital admissions covering all secondary NHS healthcare services in England obtained by linking to HES. The other advantage was that we compared people with SMI inclusively with the general population, resulting in more conservative estimation of the relative risk of admission. Regarding limitations, first, the research cohort was constructed based on a case registry and thus used data that were not collected for research purposes. Thus, information might have been incomplete or of uncertain quality, especially with respect to trajectories of treatment and time-varying exposures to psychotropic medication among older cohort members with SMI. Second, the classification of admission causes may have been a slightly crude means of identifying specific admission causes of clinical importance, restricting the possibility of further exploration of those diseases.Reference Hendrie, Tu, Tabbey, Purnell, Ambuehl and Callahan3,Reference Davydow, Ribe, Pedersen, Fenger-Gron, Cerimele and Vedsted33 In addition, the generalisability of our results could be constrained by the sample being limited to an urban and suburban catchment area in south London; the findings need to be more widely replicated by studies in various settings in the future. Moreover, the results of indirect standardisation were not directly comparable across studies, which further restricted the explainability of the current analyses. Last, no confounders other than age, sex and year were controlled in the process of indirect standardisation for SARs, for instance, smoking, drinking and obesity. The potential for overestimation of the SARs should be borne in mind in any further implementation or policy-making. Nonetheless, in the analysis of length of hospital stay in days, we further controlled for ethnicity, method of discharge and number of other physical comorbidities as potential confounders in addition to the matched ones (age, sex and admission cause).
Public health implications and future directions
The findings of our study underline the importance of monitoring the physical health status of older people with SMI in the community, rather than focusing only on psychiatry treatments.Reference Pearson, Siskind, Hubbard, Gordon, Coulson and Warren29 Early detection, followed by effective intervention to prevent hospital admission, is critical for this vulnerable group. The coverage and frequency of screening projects for illnesses of critical concern in older people should be enhanced, particularly for those with SMI.Reference Konz, Meesters, Paans, van Grootheest, Comijs and Stek50,Reference Tuesley, Jordan, Siskind, Kendall and Kisely51 Improving healthcare services for these individuals requires a well-integrated health management system with organised coordination of health promotion activities, highly accessible primary care, and timely referrals to secondary healthcare services with continuity.Reference Hendrie, Tu, Tabbey, Purnell, Ambuehl and Callahan3,Reference Arbus, Clement, Bougerol, Fremont, Lancrenon and Camus30,Reference Bartels, Pratt, Mueser, Naslund, Wolfe and Santos52,Reference Hoertel, Limosin and Leleu53 The provision of appropriate primary care and health promotion for older people with SMI will help health service providers to meet their persistent needs with respect to both physical and mental healthcare.Reference Pearson, Siskind, Hubbard, Gordon, Coulson and Warren29,Reference Beunders, Kok, Kosmas, Beekman, Sonnenberg and Schouws34 Future work should investigate potential barriers to access to appropriate health management programmes, as well as the delivery of timely primary and secondary medical services.Reference Muralidharan, Klingaman, Prior, Molinari and Goldberg31,Reference Bartels, Pratt, Mueser, Naslund, Wolfe and Santos52,Reference Gilbody, Peckham, Bailey, Arundel, Heron and Crosland54 Research on the role of autonomic dysfunction in SMI treatments and illnesses is warranted as well.Reference Pearson, Siskind, Hubbard, Gordon, Coulson and Warren29,Reference Alvares, Quintana, Hickie and Guastella43
Supplementary material
Supplementary material is available online at https://doi.org/10.1192/bjp.2024.765.
Data availability
From 3 months to 5 years following the publication of this article, data of individual participants will be available to researchers who provide a methodologically sound research proposal with approval. Data collected for all of the individual participants involved in current analyses will be shared under the UK regulations for anonymised electronic health records. Our detailed study protocol and statistical analysis plan will also be available. Requests and proposals should be directed to chinkuochang@ntu.edu.tw. To gain access, data requestors must sign a data access agreement for legal reasons.
Author contributions
C.-K.C. and Y.-P.S., the guarantors, accept full responsibility for the work and the conduct of the study, have access to the data, and control the decision to publish. C.-K.C., Y.-P.S., R.D.H., M.B., P.D.M. and R.S. took on the work of conceptualisation and study design. Methodology issues were addressed by C.-K.C. and Y.-P.S. C.-K.C., M.B. and H.S. accessed and verified data reported. Data were analysed by C.-K.C. Figures and tables were generated by C.-K.C. and Y.-P.S. All authors were responsible for data interpretation, writing the original draft, and reviewing and editing the final manuscript. R.S. supervised the work. C.-K.C. and Y.-P.S. attest that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.
Funding
This work utilised the Clinical Record Interactive Search platform, funded for development by the National Institute for Health Research Maudsley Biomedical Research Centre at South London and Maudsley National Health Service Foundation Trust and King's College London. The funder of the study had no role in study design, data collection, data analysis, interpretation of data, writing of the manuscript or the decision of submission for publication.
Declaration of interest
R.S. reports grants from Janssen and Roche and a PhD studentship funded by GlaxoSmithKline outside the submitted work. R.D.H., H.S. and R.S. have received research funding from Roche, Pfizer, Janssen, and H. Lundbeck for work outside this study. In addition, R.S. has received funding from Takeda.
eLetters
No eLetters have been published for this article.